Brain-derived neurotrophic factor and the derived dodecapeptide function as Toll-like receptor 4 antagonists in acute lung injury.

Summary

Using ALI and sepsis models, the study shows epithelial BDNF is reduced, inversely tracks inflammation, and directly antagonizes macrophage TLR4. A BDNF-derived dodecapeptide (BDP-12) preserves TLR4 antagonism and anti-inflammatory activity without pro-proliferative effects, nominating it as a therapeutic lead.

Key Findings

• BDNF is reduced in pulmonary epithelial cells and inversely correlates with inflammatory responses in ALI and sepsis models.
• Augmenting BDNF alleviates inflammatory lung injury, but this protection is lost in macrophage-deleted mice.
• Proteomics identifies macrophage TLR4 as a direct binding target of BDNF; the BDNF fragment aa104-115 mediates this interaction.
• A synthetic BDNF-derived dodecapeptide (BDP-12) retains TLR4 antagonism and anti-inflammatory effects without pro-proliferative side effects.

Clinical Implications

TLR4 antagonism via BDP-12 could represent a new class of host-directed therapy to mitigate macrophage-driven inflammation in acute lung injury secondary to sepsis, pending pharmacokinetic and safety evaluation.

Limitations

• Preclinical models without human validation; translational efficacy and safety remain to be established.
• Potential off-target effects and immunogenicity of BDP-12 were not fully characterized.
• Dose–response, pharmacokinetics, and long-term outcomes were not reported.

Future Directions

Advance BDP-12 to pharmacokinetic, toxicology, and large-animal studies; evaluate efficacy in clinically relevant sepsis-induced lung injury models and explore biomarkers for patient stratification.